ATE305612T1 - Reporterverbindungen und verfahren zur auffindung von hochspezifische proteaseaktivität - Google Patents

Reporterverbindungen und verfahren zur auffindung von hochspezifische proteaseaktivität

Info

Publication number
ATE305612T1
ATE305612T1 AT00936829T AT00936829T ATE305612T1 AT E305612 T1 ATE305612 T1 AT E305612T1 AT 00936829 T AT00936829 T AT 00936829T AT 00936829 T AT00936829 T AT 00936829T AT E305612 T1 ATE305612 T1 AT E305612T1
Authority
AT
Austria
Prior art keywords
methods
protease activity
specific protease
entity
reporter compounds
Prior art date
Application number
AT00936829T
Other languages
English (en)
Inventor
Acker Koenraad Lodewijk Au Van
Inge Dierynck
Rudi Wilfried Jan Pauwels
Original Assignee
Tibotec Bvba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Bvba filed Critical Tibotec Bvba
Application granted granted Critical
Publication of ATE305612T1 publication Critical patent/ATE305612T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/43504—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates
    • G01N2333/43595—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
AT00936829T 1999-05-26 2000-05-26 Reporterverbindungen und verfahren zur auffindung von hochspezifische proteaseaktivität ATE305612T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99201659A EP1055929A1 (de) 1999-05-26 1999-05-26 Mittel und Verfahren für Medizinentdeckung und phenotypische Charakterisierung von Zellen
PCT/EP2000/004923 WO2000073802A1 (en) 1999-05-26 2000-05-26 Reporter molecules and methods for assaying high specificity protease activity

Publications (1)

Publication Number Publication Date
ATE305612T1 true ATE305612T1 (de) 2005-10-15

Family

ID=8240238

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00936829T ATE305612T1 (de) 1999-05-26 2000-05-26 Reporterverbindungen und verfahren zur auffindung von hochspezifische proteaseaktivität
AT00941999T ATE361374T1 (de) 1999-05-26 2000-05-26 Reporterverbindungen und verfahren zur bestimmung des lipidisierungsstatus einer zelle

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT00941999T ATE361374T1 (de) 1999-05-26 2000-05-26 Reporterverbindungen und verfahren zur bestimmung des lipidisierungsstatus einer zelle

Country Status (9)

Country Link
US (1) US7129036B1 (de)
EP (3) EP1055929A1 (de)
AT (2) ATE305612T1 (de)
AU (2) AU778272B2 (de)
CA (2) CA2374047A1 (de)
DE (2) DE60022879T2 (de)
DK (1) DK1185873T3 (de)
ES (1) ES2249273T3 (de)
WO (2) WO2000073497A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756207B1 (en) 1997-02-27 2004-06-29 Cellomics, Inc. System for cell-based screening
US8815577B2 (en) * 2001-07-30 2014-08-26 Meso Scale Technologies, Llc Assay electrode having immobilized lipid/protein layers, methods of making the same and methods of using the same for luminescence test measurements
CN100535123C (zh) * 2001-08-10 2009-09-02 阿赫姆生物系统公司 蛋白酶检测系统
US8367318B2 (en) 2007-07-23 2013-02-05 Dharmacon, Inc. Screening of micro-RNA cluster inhibitor pools
WO2009100760A1 (en) * 2008-02-13 2009-08-20 Novartis Ag Cellular screening assay for modulators of mevalonate pathway
WO2013134499A1 (en) 2012-03-07 2013-09-12 The Johns Hopkins University Anastasis biosensor
EP3542162B1 (de) * 2016-11-16 2021-09-01 The Johns Hopkins University Anastasebiosensor
US11649509B2 (en) 2017-11-16 2023-05-16 The Johns Hopkins University Anastasis biosensor caspase tracker
CN113444834B (zh) * 2020-03-27 2026-02-10 天津师范大学 2019新型冠状病毒lamp检测的引物组、双重恒温显色试剂盒及检测方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9226065D0 (en) * 1992-12-14 1993-02-10 Ici Plc Peptides
ATE211506T1 (de) * 1995-01-31 2002-01-15 Bioimage As Ein verfahren zum nachweis biologisch aktiver substanzen
US6153380A (en) * 1996-01-23 2000-11-28 Rigel Pharmaceuticals, Inc. Methods for screening for transdominant intracellular effector peptides and RNA molecules
DK0986753T4 (da) * 1997-04-07 2005-12-19 Bioimage As Fremgangsmåde til uddragning af kvantitativ information, hvad angår en påvirkning af et cellulært respons
PL341661A1 (en) * 1997-10-10 2001-04-23 Cytovia Novel fluorescent reporter particles and their application in combination with testing capsizes

Also Published As

Publication number Publication date
EP1185873B1 (de) 2005-09-28
ATE361374T1 (de) 2007-05-15
US7129036B1 (en) 2006-10-31
DE60022879T2 (de) 2006-07-20
EP1055929A1 (de) 2000-11-29
EP1185873A1 (de) 2002-03-13
AU5217700A (en) 2000-12-18
DE60034672D1 (de) 2007-06-14
EP1185873B8 (de) 2005-11-23
AU5676700A (en) 2000-12-18
ES2249273T3 (es) 2006-04-01
WO2000073497A1 (en) 2000-12-07
AU777118B2 (en) 2004-09-30
CA2374038A1 (en) 2000-12-07
AU778272B2 (en) 2004-11-25
EP1185689B1 (de) 2007-05-02
EP1185689A1 (de) 2002-03-13
CA2374047A1 (en) 2000-12-07
WO2000073802A1 (en) 2000-12-07
DE60022879D1 (de) 2006-02-09
DK1185873T3 (da) 2006-01-30

Similar Documents

Publication Publication Date Title
BR0207775A (pt) Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
DE69941429D1 (de) 1-deoxy-galactonojirimycin-derivate zur vewendung bei der behandlung von lysosomalen speicherkrankheiten mittels steigerung der lysosomalen alpha galactosidase a
NO993709D0 (no) Stabilisert blanding omfattende fibrinogen
EP1131333A4 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
ATE329897T1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiven substanzen
TR200201058T2 (tr) P38 protein kinaz inhibitörleri olarak, alkilaminoyla ornatılmış bisiklik, azotlu heterosikller
EA200501772A1 (ru) Способы измерения экспрессии генов из фиксированного и залитого в парафин образца ткани
ATE500323T1 (de) Subtilisin-variante
EP1322307A4 (de) Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen
EA200400241A1 (ru) Направленные к мишени мультимерные контрастные вещества, основанные на пептидах
DE69714654D1 (de) Verwendung von einem Metalloporphyrinkonjugat für den Nachweis biologischer Verbindungen
DE60021898D1 (de) Reverse-turnmimetika und damit zusammenhängendes verfahren
MXPA03001495A (es) Derivados de fenilalanina novedosos.
NO20000862D0 (no) Elektrokjemisk system for bestemmelse av blodkoaguleringstid
UY34152A (es) ?oxazolidinonas substituidas y su uso?.
ATE196637T1 (de) Dipeptidische benzamidine als kininogenasen- inhibitoren
GR890100846A (el) Μεθοδος μετατροπης κυτταρικης διαφοροποιησης και λειτουργιας καισυνθεσεις της.
EE05558B1 (et) Antikeha v?i selle antigeeni siduva fragmendi v?i lahustuva polpeptiidi kasutamine farmatseutilise kompositsiooni valmistamiseks
DE69825625D1 (de) Aminobiguanide und ihre verwendung zur desinfektion von kontaktlinsen und konservierung von pharmazeutischen zubereitungen
DE60022879D1 (de) Reporterverbindungen und verfahren zur auffindung von hochspezifische proteaseaktivität
TR199900596T2 (xx) Otoim�n hastal�klara kar�� maddeler olarak proteinlerin kullan�m�.
DK1015437T3 (da) Benzoxazin- og benzothiazin-derivater og deres anvendelse i lægemidler
BR0114884A (pt) Compostos calcilìticos
IT1299201B1 (it) Fibroblasti modificati geneticamente e loro uso
TR199900480T2 (xx) Kristalin farmas�tik �r�n.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1185873

Country of ref document: EP

REN Ceased due to non-payment of the annual fee